Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2017
|
| _version_ | 1826295835046969344 |
|---|---|
| author | Mease, P Kavanaugh, A Coates, L McInnes, I Hojnik, M Zhang, Y Anderson, J Dorr, A Gladman, D |
| author_facet | Mease, P Kavanaugh, A Coates, L McInnes, I Hojnik, M Zhang, Y Anderson, J Dorr, A Gladman, D |
| author_sort | Mease, P |
| collection | OXFORD |
| description | To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the association of MDA status with independent quality of life (QoL)-related patient-reported outcomes (PROs).Univariate and multivariate analyses were used to identify the baseline characteristics that predicted achievement of MDA at individual time points (weeks 12 through 144) or sustained MDA (achievement of MDA at 2 consecutive time points 12 weeks apart). The association of independent QoL-related PROs with MDA achievement was evaluated at weeks 24 and 144.In univariate analyses, higher baseline patient assessment of pain, tender joint count (TJC), enthesitis and Health Assessment Questionnaire-Disability Index (HAQ-DI) score were significantly associated with lower likelihood of achieving MDA at later time points. Multivariate analyses confirmed higher baseline HAQ-DI as a significant predictor for failure to achieve MDA at later time points. Achievement of sustained MDA was associated with lower baseline TJC and HAQ-DI score. Achievement of different MDA components appeared to be treatment dependent. MDA achievers had significantly better QoL-related PROs and greater improvements in PROs from baseline to week 24 compared with non-achievers.Higher HAQ-DI score was the most consistent baseline factor that decreased the likelihood of achieving MDA and sustained MDA at later time points. Achieving MDA was associated with better independent QoL-related PROs. |
| first_indexed | 2024-03-07T04:07:05Z |
| format | Journal article |
| id | oxford-uuid:c68a6b99-49c1-4216-8a2c-fc83220c99c5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:07:05Z |
| publishDate | 2017 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:c68a6b99-49c1-4216-8a2c-fc83220c99c52022-03-27T06:38:51ZPrediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c68a6b99-49c1-4216-8a2c-fc83220c99c5EnglishSymplectic Elements at OxfordBMJ Publishing Group2017Mease, PKavanaugh, ACoates, LMcInnes, IHojnik, MZhang, YAnderson, JDorr, AGladman, DTo determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the association of MDA status with independent quality of life (QoL)-related patient-reported outcomes (PROs).Univariate and multivariate analyses were used to identify the baseline characteristics that predicted achievement of MDA at individual time points (weeks 12 through 144) or sustained MDA (achievement of MDA at 2 consecutive time points 12 weeks apart). The association of independent QoL-related PROs with MDA achievement was evaluated at weeks 24 and 144.In univariate analyses, higher baseline patient assessment of pain, tender joint count (TJC), enthesitis and Health Assessment Questionnaire-Disability Index (HAQ-DI) score were significantly associated with lower likelihood of achieving MDA at later time points. Multivariate analyses confirmed higher baseline HAQ-DI as a significant predictor for failure to achieve MDA at later time points. Achievement of sustained MDA was associated with lower baseline TJC and HAQ-DI score. Achievement of different MDA components appeared to be treatment dependent. MDA achievers had significantly better QoL-related PROs and greater improvements in PROs from baseline to week 24 compared with non-achievers.Higher HAQ-DI score was the most consistent baseline factor that decreased the likelihood of achieving MDA and sustained MDA at later time points. Achieving MDA was associated with better independent QoL-related PROs. |
| spellingShingle | Mease, P Kavanaugh, A Coates, L McInnes, I Hojnik, M Zhang, Y Anderson, J Dorr, A Gladman, D Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial |
| title | Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial |
| title_full | Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial |
| title_fullStr | Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial |
| title_full_unstemmed | Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial |
| title_short | Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial |
| title_sort | prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the adept trial |
| work_keys_str_mv | AT measep predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT kavanaugha predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT coatesl predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT mcinnesi predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT hojnikm predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT zhangy predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT andersonj predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT dorra predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial AT gladmand predictionandbenefitsofminimaldiseaseactivityinpatientswithpsoriaticarthritisandactiveskindiseaseintheadepttrial |